Other Events ·
Stoke Therapeutics, Inc. announced the completion of patient enrollment for its Phase 3 EMPEROR study of zorevunersen…
STOKStoke Therapeutics, Inc.
Stoke Therapeutics, Inc. announced the completion of patient enrollment for its Phase 3 EMPEROR study of zorevunersen for Dravet syndrome, enrolling 162 patients across the U.S., U.K., and Japan. A Phase 3 data readout is expected in the third quarter of 2027, and the company plans to initiate a rolling New Drug Application (NDA) submission to the FDA in the first quarter of 2027. Stoke Therapeutics, Inc. is a biotechnology company developing potential disease-modifying treatments for genetic neurological disorders.